Plasma Protease C1-inhibitor Treatment; Used to Treat Hereditary Angioedema and Diabetic Macular Edema
Plasma protease C1-inhibitor treatment is widely used to treat various health conditions, such as diabetic macular edema, hereditary angioedema, and others. Hereditary angioedema is an autosomal disorder characterized by low levels of functional C1 esterase inhibitor protein. C1 esterase inhibitors are widely used for the treatment of hereditary angioedema. Hereditary angioedema treatment consists of prophylaxis, management of acute attacks, and prophylactic therapy in situations where attacks may occur. Moreover, there are several U.S. FDA (United States Food and Drug Administration) approved plasma protease C1-inhibitor treatment to treat Hereditary angioedema C1 esterase inhibitor. Several plasma protease C1-inhibitor treatment, such as Berinet, Kalbitor, Firazyr, and Cinryze have been approved for the acute and prophylactic attack treatment of hereditary angioedema. The main function of C1-inhibitor (C1 esterase inhibitor) is the inhibition of the complement system to prevent